Bile Acids in Neurodegenerative Disorders
Hayley D Ackerman1, Glenn S Gerhard1
1Department of Medical Genetics and Molecular Biochemistry, The Lewis Katz School of Medicine at Temple University Philadelphia, PA, USA.
Frontiers in Aging Neuroscience
|December 7, 2016
Summary
Bile acids show potential for treating neurodegenerative diseases, but their exact mechanisms and origins in the nervous system require further research for clinical application.
Area of Science:
- Biochemistry
- Neuroscience
- Pharmacology
Background:
- Bile acids, cholesterol-derived molecules, have historical and modern therapeutic uses, particularly in liver diseases.
- Emerging evidence suggests bile acids possess neuroprotective properties against age-related neurodegenerative disorders.
- Despite pilot clinical trials, their precise roles and mechanisms within the nervous system remain largely unknown.
Approach:
- This review synthesizes existing data on bile acids as potential treatments for neurodegenerative diseases.
- It examines the molecular basis and evidence from cellular, animal, and human studies.
- The focus is on understanding their neuroprotective effects and identifying knowledge gaps.
Key Points:
- Bile acids are being investigated for their neuroprotective effects in various neurodegenerative conditions.
- Data from preclinical models and early clinical trials indicate potential therapeutic benefits.
- The specific bile acids involved, their endogenous production in the brain, and their exact molecular targets are not yet fully elucidated.
Conclusions:
- While promising, the translation of bile acids into effective treatments for neurodegenerative diseases is hindered by incomplete understanding of their mechanisms.
- Further research is crucial to identify the key bile acids, their origins, and their neuroprotective pathways.
- Clarifying these aspects will accelerate the development of novel therapies for neurological disorders.
Related Concept Videos
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Role of Neurotransmitters in Memory
2.8K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.8K
Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Amyloid Fibrils
6.9K
6.9K
The Blood-brain Barrier
54.4K
Overview
54.4K


